| Document |
Document Title |
|
WO/2020/179489A1 |
This compound has a perovskite type crystal structure including, as constituting components, A which is a monovalent cation, B which is a metal ion, and X which is a halide ion, wherein the unit lattice volume thereof is 0.2000-0.2150 nm...
|
|
WO/2020/177778A1 |
The present invention discloses a 1-pyridylpyrazole amide compound represented by formula (I), the preparation method and application thereof, and each substituent in the formula has the definition given by the description. The compound ...
|
|
WO/2020/175671A1 |
A polymer which has a constituent component represented by formula (I); a method for producing this polymer; a diamine compound which is useful as a starting material for this polymer; a gas separation membrane which has a gas separation...
|
|
WO/2020/174030A1 |
Acatalyst composition comprising at least one compound with a general formula (I) wherein A is N-R3, R3 is C1-C8 linear or branched, x = 0-6, n and m are each independently 1 to 6, R1 and R2 are each independently C2 -C8 alkyl, and R4 an...
|
|
WO/2020/175309A1 |
This catalyst for amide compound hydrogenation is capable of carrying out a reduction reaction that converts an amide compound into an amine compound, and is characterized by including rhodium and molybdenum being supported on hydroxyapa...
|
|
WO/2020/175380A1 |
Provided are a novel amine composition and amine compound. Provided are a production method thereof, as well as an epoxy resin curing agent, an epoxy resin composition, a cured product, a urethane prepolymer curing agent, a polyurethane ...
|
|
WO/2020/174346A1 |
The present invention relates to a novel tetraarylborate compound, a catalyst composition comprising same, and a method for preparing ethylene homopolymers or copolymers of ethylene and α-olefins by using same. In detail, the tetraarylb...
|
|
WO/2020/170080A1 |
A hydrofluoroolefin compound is represented by the following general formula (I): where RF1 is a hydrogen atom or CH3, and (iii) RF1 is a linear or branched perfluorinated alkyl group having 1 to 10 carbon atoms and optionally including ...
|
|
WO/2020/170971A1 |
The first objective of the present invention is to provide a composition which enables the achievement of a cured product that has excellent antibacterial properties. The second objective of the present invention is to provide a cured pr...
|
|
WO/2020/169060A1 |
Disclosed is an organic compound having a spirobifluorene structure containing a diarylamine substituent group, having a structure as shown in formula (1). The compound has a non-planar spatial structure, a higher glass transition temper...
|
|
WO/2020/171210A1 |
The phytol contained in watermelon sprouts is known to have a cancer cell growth inhibiting effect. The problem, however, is the amount ingested to inhibit cancer cell growth is large. A cancer cell growth inhibiting composition having...
|
|
WO/2020/163966A1 |
The use of pharmaceutically active compounds for treating chronic lung diseases including idiopathic pulmonary fibrosis is disclosed. The compounds include NMDA receptor antagonists, glutamate 2b receptor antagonists and sigma receptor a...
|
|
WO/2020/166677A1 |
Provided is, inter alia, a processing solution for semiconductor wafers for use in a semiconductor formation process. Provided is, inter alia, a processing solution that contains (A) hypochlorite ions and (B) an alkylammonium salt repres...
|
|
WO/2020/166984A1 |
The present invention pertains to: CPNA prepared by reacting 4-CA and F-NO2 with a polar aprotic solvent having a boiling point higher than the reaction temperature, and CPDA prepared by reacting 4-CA and F-NO2 with a sulfur compound hav...
|
|
WO/2020/165338A1 |
The invention pertains to a process for manufacturing ethyleneamine compounds selected from the group of ethyleneamines and hydroxyethylethyleneamines wherein the process comprises two reaction sequences, the first reaction sequence comp...
|
|
WO/2020/167948A1 |
Provided herein are compositions and methods for improving outcome in stem cell transplantation. In particular, provided herein are compositions and methods for improving efficacy and reducing graft versus host disease in allogenic cell ...
|
|
WO/2020/165330A1 |
Process for manufacturing ethyleneamine compounds selected from the group of ethyleneamines and hydroxyethylethyleneamines wherein the process comprises two reaction sequences, the first reaction sequence comprising the steps of: - in an...
|
|
WO/2020/162408A1 |
The present invention has the effect of making it possible to produce 1,1,1-trifluoro-2,2-bisarylethane efficiently by a simple procedure by condensing a mixture of fluoral and hydrogen fluoride with an aryl compound under anhydrous cond...
|
|
WO/2020/163839A1 |
The present invention provides ionic liquids (ILs) comprising a carbohydrate anionic moiety and a cationic counter-ion moiety (Q+) and methods for producing and using the same. In one particular embodiment, the carbohydrate anionic moiet...
|
|
WO/2020/163746A1 |
The invention provides for compounds that are HAT activators or inhibitors. The invention further provides a method for treating neurodegenerative diseases, cancer and other malignant conditions, or to increase memory in a subject not su...
|
|
WO/2020/156312A1 |
The present invention relates to a polycyclic derivative modulator, a preparation method therefor and an application thereof. In particular, the present invention relates to a compound represented by general formula (I), a preparation me...
|
|
WO/2020/159135A1 |
The present invention provides: a compound represented by chemical formula 1; an organic electric element comprising a first electrode, a second electrode, and an organic material layer between the first electrode and the second electrod...
|
|
WO/2020/151500A1 |
Disclosed herein are an organic electroluminescent compound, an electroluminescent material and an organic electroluminescent component. The organic electroluminescent compound has the structure of formula (1). The organic electrolumines...
|
|
WO/2020/151499A1 |
Disclosed are a fluorene derivative and an electronic device. Fluorene rigid structure, fluorene derivative film forming ability and thermal stability make the fluorene derivative disclosed herein an excellent candidate for preparing an ...
|
|
WO/2020/154320A1 |
The present disclosure addresses elastomeric adhesives and elastomers that include a modified amine. The modified amine can be the reaction product of an amine with a Michael acceptor. The amine can be represented by H2N-Ar-R1-NH2, where...
|
|
WO/2020/148617A1 |
The present invention disclosed 3-substituted phenylamidine compounds of general formula (I), wherein R1, R2, R3, R4, R4a, R4b, A and E have the same meanings as defined in description. The present invention further discloses methods for...
|
|
WO/2020/149710A1 |
The present invention provides: a compound represented by chemical formula 1; an organic electronic element including a first electrode, a second electrode, and an organic layer formed between the first electrode and the second electrode...
|
|
WO/2020/142545A1 |
Provided are methods of using (1R,5S)-1-(3,4-dichlorophenyl)-3-azabicyclo[3.1.0]hexane, in free or pharmaceutically acceptable salt form.
|
|
WO/2020/141419A2 |
The present invention relates to novel pharmaceutically acceptable salts of Bempedoic acid, novel intermediates of Bempedoic acid, novel crystalline form of Bempedoic acid and novel processes for the preparation of Bempedoic acid or its ...
|
|
WO/2020/140187A1 |
The present invention belongs to the technical field of organic synthesis, and particularly relates to a method for preparing a high purity dimethyl diallyl ammonium chloride monomer in high yield. The preparation method provided by the ...
|
|
WO/2020/135569A1 |
The present invention relates to the field of medicinal chemistry, and relates to an ethylenediamine compound represented by formula A, pharmaceutically acceptable salts, stereoisomers, tautomers or isomer mixtures thereof, hydrates ther...
|
|
WO/2020/138389A1 |
Provided are: a novel nanoparticle; a contrast agent for magnetic resonance imaging comprising the same; and a zwitterionic ligand compound to be used in the production of the nanoparticle. The contrast agent for MRI according to the pre...
|
|
WO/2020/138837A1 |
The present invention relates to a compound represented by chemical formula 1, an organic optoelectronic device, and a display device.
|
|
WO/2020/133022A1 |
The present invention relates to a Cypyrafluone dimethylamine salt, a preparation method therefor, and use thereof. The present invention specifically relates to a crystal form A of the Cypyrafluone dimethylamine salt, and the X-ray powd...
|
|
WO/2020/130511A1 |
The present specification pertains to: a compound of chemical formula 1; and an organic light-emitting device including same.
|
|
WO/2020/129749A1 |
The present invention provides a method for producing primary amines and secondary amines, the method being characterized by reducing a primary amide or a secondary amide in the presence of a reducing agent and an organic metal halide of...
|
|
WO/2020/132406A1 |
The present invention is directed to a method for making a di(aminoaryl)fluorene compound that includes the steps of: (a) reacting a fluorenone compound according structure (I) with excess aminobenzene according to structure (II) wherein...
|
|
WO/2020/126819A1 |
The present invention relates to a process for preparing compounds of the formula (I), starting from compounds of the formula (II), wherein R1, R2, R3 and R3' are defined according to the invention.
|
|
WO/2020/132196A1 |
Nanoparticle compositions for delivery of nucleic acids to subjects including modified dendrimers comprising cores, one or more of homogeneous or heterogeneous intermediate and terminal layers, and therapeutic or immunogenic nucleic acid...
|
|
WO/2020/130623A1 |
The present specification provides a compound of chemical formula 1 and an organic light-emitting device comprising same.
|
|
WO/2020/119595A1 |
Provided are a phenol salt and application thereof as a catalyst in a hexavalent sulfur-fluoride exchange reaction, said phenol salt comprising cations and anions. The phenol salt is easy to synthesize and can be used as a catalyst for a...
|
|
WO/2020/120637A1 |
The application relates to a compound of formula (I) or a pharmaceutical salt thereof of formula (II), as well as to a process to obtain said compound and a process to obtain said salt. Additionally disclosed is the compound of formula (...
|
|
WO/2020/117654A1 |
The invention is directed at esylate and salicylate salts of cis-N-cyclohexyl-N-ethyl-3-(3-chloro-4-cyclohexylphenyl)prop
-2-enylamine and their pharmaceutical composition. The invention is also directed at the use esylate and salicylate...
|
|
WO/2020/116418A1 |
A compound represented by formula (1). (In the formula, R1-R4 and L1-L4 are as defined in the description; Ar represents a moiety of formula (A) or (B) (wherein R11-R18 and R20-R29 are as defined in the description); and Ar is as defined...
|
|
WO/2020/112357A1 |
Provided herein are compounds of Formula (I), including methods of making the same. The disclosed compounds are succinate dehydrogenase inhibitors and can be useful in, e.g., inhibiting or preventing fungal growth.
|
|
WO/2020/113028A1 |
The present disclosure provides, inter alia, a compound having the structure (1). Also provided are compositions containing a pharmaceutically acceptable carrier and one or more compounds according to the present disclosure. Further prov...
|
|
WO/2020/102936A1 |
A method for preparing a covalent organic framework (COF) material and a method for reversible condensation polymerization/termination polymerization. The COF material prepared by the present method shows high crystallinity, high specifi...
|
|
WO/2020/103006A1 |
A process for preparing a primary amine by reacting an alcohol with ammonia in the present of a metal catalyst comprising metal nanoparticles, wherein the metal nano-particles comprises at least one transition metal in elemental form and...
|
|
WO/2020/106098A1 |
The present specification relates to a compound of chemical formula 1 and an organic light-emitting diode comprising same.
|
|
WO/2019/079607A9 |
The present disclosure relates to a method of preventing or treating a blood disorder (e.g., sickle-cell disease) via administering an EHMT2 inhibitor compound disclosed herein or a pharmaceutical composition thereof to subjects in need ...
|
